>
Switch to:

NovoCure Earnings Yield (Joel Greenblatt) %

: -0.08% (As of Sep. 2021)
View and export this data going back to 2015. Start your Free Trial

NovoCure's Enterprise Value for the quarter that ended in Sep. 2021 was $11,699.6 Mil. NovoCure's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 was $-8.8 Mil. NovoCure's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2021 was -0.08%.

The historical rank and industry rank for NovoCure's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

NAS:NVCR' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33.43   Med: -0.72   Max: 0.29
Current: -0.13

-33.43
0.29

During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of NovoCure was 0.29%. The lowest was -33.43%. And the median was -0.72%.

NAS:NVCR's Earnings Yield (Joel Greenblatt) % is ranked lower than
52% of the 803 Companies
in the Medical Devices & Instruments industry.

( Industry Median: 0.42 vs. NAS:NVCR: -0.13 )

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. NovoCure's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2021 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


NovoCure Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for NovoCure's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Earnings Yield (Joel Greenblatt) %
Premium Member Only Premium Member Only Premium Member Only -20.62 -2.22 -1.07 0.06 0.18

NovoCure Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Earnings Yield (Joel Greenblatt) % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.18 0.25 0.07 -0.08

Competitive Comparison

For the Medical Instruments & Supplies subindustry, NovoCure's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

NovoCure Earnings Yield (Joel Greenblatt) % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where NovoCure's Earnings Yield (Joel Greenblatt) % falls into.



NovoCure Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

NovoCures Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2020 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=30.401/17309.49736
=0.18 %

NovoCure's EBIT for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.8 Mil.



NovoCure  (NAS:NVCR) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


NovoCure Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of NovoCure's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

NovoCure logo
Industry
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, Saint Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
Executives
Weinberg Uri officer: Chief Science Officer NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Groenhuysen Wilhelmus Cm officer: Chief Operating Officer C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654
Danziger Asaf director, officer: Chief Executive Officer 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302
Leung Gabriel director C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960
Shah Pritesh officer: Chief Commercial Officer C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Leonard Frank X officer: Chief Development Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Cordova Ashley officer: Chief Financial Officer 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355
Madden Martin J. director C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043
Benaim Ely officer: Chief Medical Officer C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850
Doyle William F director, officer: Executive Chairman PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Ambrogi Michael J. officer: Chief Operating Officer 195 COMMERCE WAY PORTSMOUTH NH 03801
Longsworth Todd Christopher officer: General Counsel NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355
Hilleman Jeryl L director C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mccoy Sherilyn S director JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933
Hung David director C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018

NovoCure Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)